|
Modality | Cell type | Immune component | Species | Ref. |
|
RFA | | | | |
Potential tumor suppression | | | | |
| VX2 | tumor-specific T-cells; T-cell infiltration | Rabbit | [44] |
| HCC | DC activation; serum TNF-, IL-1 | Human | [31] |
| HCC | Tumor-specific CD4+ and CD8+ response | Human | [90] |
| HCC | HSP70 in tumor cell surface and cytoplasm | Human | [91] |
| Primary and metastatic liver, kidney, and lung cancer | HSP70 | Human | [41] |
| Primary and metastatic liver tumors | memory T-cell trafficking, T-cell proliferation in metastatic cancer patients | Human | [92] |
| HCC | tumor-specific CD8+, correlating with progression-free survival after ablation | Human | [43] |
| Primary and metastatic lung tumors | ; serum IL-8, IL-10, C3, C4, and CRP | Human | [32] |
| Colon and kidney tumors and melanoma | antigen-specific antibodies, CD4+ and CD8+ T-cells | Human | [46] |
| HCC | NK cell stimulation | Human | [93] |
| Primary and metastatic colon, liver, kidney, and lung tumors, melanoma, and sarcoma | serum IL-6, IL-10; serum TNF-, IL-1, and IL-2 | Human | [33] |
| Melanoma | Reduced tumor recurrence when combined with DC tumoral vaccine | Mouse | [86] |
| Melanoma | DC activation; immunization against rechallenge with anti-CTLA-4 therapy | Mouse | [9, 94] |
| Urothelial cancer | Tumor-specific T-cell activation, immunization against rechallenge | Mouse | [37] |
| Hepatocytes | IL-6 | Rat | [34] |
| Hepatocytes | apoptosis, HSP70 in transition zone | Pig | [95] |
Potential tumor stimulation | | | | |
| Hepatocytes | intracellular HSP70 expression in tumor cells near blood vessels | Rat | [96] |
| Hepatocytes (MDR2 knockout) | tumor development, survival; effect diminished with c-Met inhibitor | Mouse | [3] |
| Hepatocytes | breast cancer xenograft growth; effect diminished with c-Met/VEGF inhibitors | Rat | [47] |
| Colorectal | hypoxia, HIF-1, and HIF-2 in transition zone leading to tumor growth | Mouse/rat | [49] |
| HCC | HIF-1, VEGF, and angiogenesis | Mouse | [51] |
| Hepatocytes | breast cancer xenograft growth; effect diminished with anti-IL-6 siRNA | Mouse/rat | [54] |
Cryoablation | | | | |
Potential tumor suppression | | | | |
| Prostate | Remission of metastases following prostate cryoablation | Human | [55, 58] |
| Sarcoma | Regression of remote tumor; immunization against rechallenge | Rat | [57] |
| Breast | Tumor-specific T-cell response; immunization against rechallenge | Mouse | [61] |
| Melanoma | Combination with TLR9 stimulation reduces local and remote tumors | Mouse | [83] |
| Melanoma | DC activation; immunization against rechallenge with anti-CTLA-4 therapy | Mouse | [9] |
| HCC | IL-6, CRP, and IL-10; TNF- and Th1/Th2 associated with remote tumor regression | Human | [97] |
| Prostate | TNF-, IFN-, and Th1/Th2; tumor-specific T-cell response | Human | [98] |
| Lung metastases | Combination with GM-CSF caused tumor-specific T-cell response and anti-tumor antibodies | Human | [88] |
| Lung tumor, melanoma | Combination with DC therapy tumor-specific CD8+ T-cell response, survival | Mouse | [82] |
| Colon | DC + Bacillus Calmette-Guérin cell wall skeleton caused tumor-specific CD8+ T-cell response and local and remote tumor regression | Mouse | [99] |
Potential tumor suppression | | | | |
| Fibrosarcoma | mortality from metastases compared to surgical excision; excision of cryoablated tumor reduced rate of metastasis | Rat | [64] |
| Fibrosarcoma | growth of pulmonary metastases after cryoablation of flank tumor | Rat | [65] |
| Breast | Low freeze rate can , remote metastases, and survival | Mouse | [68] |
|